Showing results (2381-2390 of 2,449) with videos related to

Sort By:
Pageof 245
Cancer Research|February 4, 2026
ZNF395 Is a Hypoxia-Responsive Regulator of Mitochondrial Glutaminolysis in Clear Cell Renal Cell CarcinomaJoanna Koh, Chengheng Liao, Michelle Shu Wen Ng, et al.
Lancet (London, England)|December 5, 2012
Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort studyZhongwei Jia, Yurong Mao, Fujie Zhang, et al.
Journal of the National Cancer Center|January 7, 2026
Do ethnic disparities exist in disease burden and healthcare utilization of male breast cancer? A 9-year cohort study of 9.08 million adults in ChinaJieying Chen, Liying Qiao, Ying Yan, et al.
International Journal of Surgery (London, England)|April 12, 2024
Higher disease burden and lower utilization in Mongolian with breast cancer: a 9-year retrospective cohort study of 18.19 million adults in ChinaJieying Chen, Liying Qiao, Meng Qi, et al.
Nature Communications|June 2, 2026
Mevalonate pathway rewiring driven by enhancer remodelling confers resistance to KRAS inhibitors in colorectal cancerYaoyu Guo, Yi Zhong, Peishan Hu, et al.
Cancer Letters|June 22, 2024
CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphomaYali Wang, Jianfeng Chen, Yan Gao, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|September 12, 2013
[Population characteristics and impact on heart rate variability, heart rate and blood pressure of passive smoking]Jing Zhao, Fei He, Da-yi Hu, et al.
Scientific Reports|May 11, 2026
Integrative genomic, transcriptomic, and metabolomic profiling of Dillenia suffruticosaSabri Mohd Ali, Khwanta Kaewnarin, Abner Herbert Lim, et al.
Zhonghua Xin Xue Guan Bing Za Zhi|February 15, 2014
[Effect of the smoking cessation services in the out-patient department for patients with coronary heart disease]Jing Zhao, Jian-jun Gou, Da-yi Hu, et al.
Leukemia & Lymphoma|September 16, 2015
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasmsXing-Nong Ye, Xin-Ping Zhou, Ju-Ying Wei, et al.
Pageof 245